Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma
This article was originally published in The Pink Sheet Daily
Germany's 2011 pharmaceutical prescribing report shows that the cost control law (AMNOG) is fulfilling its purpose, prompting insurers to call for even further pressure on the industry to reduce costs.
You may also be interested in...
German elections have led to the possibility of several coalition government constellations, but none are particularly good for the pharmaceutical industry.
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.
Drug makers in Germany say this year’s widely-referenced Pharmaceutical Prescribing Report contains misleading data and warn it will be used to suppress prices even further, stifling innovation and restricting patient access to drugs.